The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody

Bibliography

• MURAGUCHI A, HIRANO T, TANG B et al.: The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. (1988) 167:332–344.
   PubMed Web of Science ®Google Scholar
• HIRANO T, YASUKAWA K, HARADA H et al.: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 324:73–76.
   PubMed Web of Science ®Google Scholar
• •Cloning of IL-6.
   Google Scholar
• HAEGEMAN G, CONTENT J, VOLCKAERT G, DERYNCK R, TAVERNIER J, FIERS W: Structural analysis of the sequence coding for an inducible 26-1cDa protein in human fibroblasts. Eur. j Biochem. (1986) 159:625–632.
   PubMedGoogle Scholar
• ZILBERSTEIN A, RUGGIERI R, KORN JH, REVEL M: Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J. (1986) 5:2529–2537.
   PubMed Web of Science ®Google Scholar
• VAN DAMME J, CAYPHAS S, VAN SNICK J et al.: Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6). Eur. J. Biochem. (1987) 168:543–550.
   Google Scholar
• GAULDIE J, RICHARDS C, HARNISH D, LANSDORP P, BAUMANN H: Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Nail. Acad. Sci. USA (1987) 84:7251–7255.
   PubMed Web of Science ®Google Scholar
• LOTZ M, JIRIK F, KABOURIDIS P et al.:B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J. Exp. Med. (1988) 167:1253–1258.
   PubMed Web of Science ®Google Scholar
• SACHS L, LOTEM J, SHABO Y: The molecular regulators of macrophage and granulocyte development. Role of MGI-2/ IL-6. Ann. NY Acad. Sci. (1989) 557:417–435.
   PubMed Web of Science ®Google Scholar
• IKEBUCHI K, WONG GG, CLARK SC, IHLE JN, HIRAI Y, OGAWA M: Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc. Nail. Acad. Sci. USA (1987) 84:9035–9039.
   PubMed Web of Science ®Google Scholar
• ISHIBASHI T, KIMURA H, UCHIDA T, KARIYONE S, FRIESE P, BURSTEIN SA: Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc. Nail. Acad. Sci. USA (1989) 86:5953–5957.
   PubMed Web of Science ®Google Scholar
• SATOH T, NAKAMURA S, TAGA T et ell.:Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/ interleukin 6. MoL Cell. Biol. (1988) 8:3546–3549.
   Google Scholar
• HAMA T, MIYAMOTO M, TSUKUI H, NISHIO C, HATANAKA H: Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neurosci. Lett. (1989) 104:340–344.
   PubMed Web of Science ®Google Scholar
• NAITOH Y, FUKATA J, TOMINAGA T et al.: Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats. Biochem. Biophys. Res. Commun. (1988) 155:1459–1463.
   PubMed Web of Science ®Google Scholar
• HEINRICH PC, CASTELL JV, ANDUS T: Interleukin-6 and the acute phase response. Biochem. J. (1990) 265:621–636.
   PubMed Web of Science ®Google Scholar
• YAMASAKI K, TAGA T, HIRATA Y et ell.: Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 241:825–828.
   Google Scholar
• •Cloning of IL-6R.
   Google Scholar
• TAGA T, HIHI M, HIRATA Y et ell.: Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 58:573–581.
   Google Scholar
• HIBI M, MURAKAMI M, SAITO M, HIRANO T, TAGA T, KISHIMOTO T: Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 63:1149–1157.
   PubMed Web of Science ®Google Scholar
• •Cloning of gp130.
   Google Scholar
• SATO K, TSUCHIYA M, SALDANHA J et al.: Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol. ImmunoL (1994) 31:371–381.
   PubMed Web of Science ®Google Scholar
• ••Humanisation of mouse anti-humanIL-6R antibody.
   Google Scholar
• GOTO H, SHIMAZAKI C, TATSUMI T et al.: Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism. Leukemia (1995) 9:711–718.
   PubMed Web of Science ®Google Scholar
• SCHWAB G, SIEGALL CB, AARDEN LA et al.: Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood (1991) 77:587–593.
   PubMed Web of Science ®Google Scholar
• HIRANO T, MATSUDA T, TURNER M et al.: Excessive production of interleukin 6/ B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol (1988) 18:1797–1801.
   PubMed Web of Science ®Google Scholar
• ••Detection of IL-6 in RA patients.
   Google Scholar
• HOUSSIAU FA, DEVOGELAER JP, VAN DAMME J, DE DEUXCHAISNES CN, VAN SNICK J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. (1988) 31:784–788.
   PubMed Web of Science ®Google Scholar
• GUERNE PA, ZURAW BL, VAUGHAN JH, CARSON DA, LOTZ M: Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J. Clin. Invest. (1989) 83:585–592.
   PubMed Web of Science ®Google Scholar
• •IL-6 production from synovium of RA patients.
   Google Scholar
• MADHOK R, CRILLY A, WATSON J, CAPELL HA: Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann. Rheum. Dis. (1993) 52:232–234.
   PubMed Web of Science ®Google Scholar
• •Correlation of IL-6 levels and disease activity of RA.
   Google Scholar
• TAMURA T, UDAGAWA N, TAKAHASHI N et al: Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA (1993) 90:11924–11928.
   PubMed Web of Science ®Google Scholar
• SUGITA T, FURUKAWA O, UENO M, MURAKAMI T, TAKATA I, TOSA T: Enhanced expression of interleukin 6 in rat and murine arthritis models. Int. J. Immunopharmacol (1993) 15:469–476.
   PubMed Web of Science ®Google Scholar
• TAKAGI N, MIHARA M, MORIOYA Y et al: Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. (1998) 41:2117–2121.
   PubMed Web of Science ®Google Scholar
• ••First paper demonstrating the preventative effect of anti-IL-6R antibody in an arthritis model.
   Google Scholar
• ALONZI T, FATTORI E, LAZZARO D et al: Interleukin 6 is required for the development of collagen-induced arthritis. 1 Exp. Med. (1998) 187:461–468.
   PubMed Web of Science ®Google Scholar
• HATA H, SAKAGUCHI N, YOSHITOMI H et at.: Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J. Clin. Invest. (2004) 114:582–588.
   Google Scholar
• IWAKURA Y, SAIJO S, KIOKA Y et al.: Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J. Immunol. (1995) 155:1588–1598.
   PubMed Web of Science ®Google Scholar
• HORAI R, SAIJO S, TANIOKA H et al.: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. 1 Exp. Med. (2000) 191:313–320.
   Google Scholar
• NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. (2004) 50:1761–1769.
   PubMed Web of Science ®Google Scholar
• ••Phase II clinical trial of tocilizumabfor RA.
   Google Scholar
• MAINI RN, TAYLOR PC, PAVELKA K et al.: CHARISMA study group: Efficacy of IL-6 receptor antibody:a multicenter,double-blind, placebo controlled trial artbritts rbeum 50:1761–1769.
   Google Scholar
• PETTY RE, SOUTHWOOD TR, BAUM J et al: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.1 Rheumatol (1998) 25:1991–1994.
   PubMedGoogle Scholar
• SAWHNEY S, WOOD P, MURRAY KJ: Macrophage activation syndrome: a poentially fatal complication of rheumatic disorders.arch dis child (2001)85:421–426.
   PubMed Web of Science ®Google Scholar
• DE BENEDETTI F, MARTINI A: Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J. Rheumatol. (1998) 25:203–207.
   Web of Science ®Google Scholar
• YOKOTA S, MIYAIVIAE T, IMAGAWA T et al.: Therapeutic efficacy of humanized recombinant anti-1L6 receptor antibody for children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. (2005) 52:818–825.
   PubMed Web of Science ®Google Scholar
• ••Clinical trial of tocilizumab for soJIA.
   Google Scholar
• IWAMOTO M, NARA H, HIRATA D, MINOTA S, NISHIMOTO N, YOSHIZAKI K: Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. (2002) 46:3388-3389. Clinical trial of tocilizumab for adult-onset Still's disease.
   Google Scholar
• MITSUYAMA K, SATA M, TANIKAWA K: Significance of interleukin- 6 in patients with inflammatory bowel disease. Gastroenterol. Jpn. (1991) 26:20–28.
   PubMedGoogle Scholar
• GROSS V ANDUS T, CAESAR I, ROTH M, SCHOLMERICH J: Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology (1992) 102:514–519.
   PubMed Web of Science ®Google Scholar
• HYAMS JS, FITZGERALD JE, TREEM WR, WYZGA N, KREUTZER DL: Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology (1993) 104:1285–1292.
   PubMed Web of Science ®Google Scholar
• ATREYA R, MUDTER J, FINOTTO S et al.: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat. Med. (2000) 6:583–588.
   PubMed Web of Science ®Google Scholar
• ••First paper demonstrating the induction of T cell apoptosis by anti-IL-6R antibody.
   Google Scholar
• YAMATOMO M, YOSHIZAKI K, KISHIMOTO T, ITO H: IL-6 is required for the development of Thl cell-mediated murine colitis. J. Immunol (2000) 164:4878–4882.
   PubMed Web of Science ®Google Scholar
• First paper demonstrating the preventative effect of anti-IL-6R antibody in a colitis model.
   Google Scholar
• ITO H, TAKAZOE M, FUKUDA Y et ed.: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 126:989-996. Clinical trial of tocilizumab for CD.
   Google Scholar
• LINKER-ISRAELI M, DEANS RJ, WALLACE DJ, PREHN J, OZERI-CHEN T, KLINENBERG JR: Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol (1991) 147:117–123.
   Google Scholar
• HIROHATA S, MIYAMOTO T: Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. (1990) 33:644-649. Expert Opin. Biol. Ther (2005) 5(5)
   Google Scholar
• GORDON C, RICHARDS N, HOWIE AJ et al.: Urinary IL-6: a marker for mesangial proliferative glomerulonephritis? Clin. Exp. Immunol (1991) 86:145–149.
   PubMed Web of Science ®Google Scholar
• MIHARA M, FUKUI H, KOISHIHARAY, SAITO M, OHSUGI Y: Immunologic abnormality in NZB/W Fl mice. Thymus-independent expansion of B cells responding to interleukin-6. Clin. Exp. Immunol (1990) 82:533–537.
   Google Scholar
• ALARCON-RIQUELME ME, MOLLER G, FERNANDEZ C: Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB x NZW)F1 hybrid. Clin. Immunol Immunopathol (1992) 62:64–69.
   Google Scholar
• MIHARA M, TAKAGI N, TAKEDA Y, OHSUGIY: IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W Fl mice. Clin. Exp. Immunol. (1998) 112:397–402.
   PubMed Web of Science ®Google Scholar
• ••First paper demonstrating the preventative effect of anti-IL-6R antibody in an SLE model.
   Google Scholar
• MIHARA M, NISHIMOTO N, YOSHIZAKI K, SUZUKI T: Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice. Immunol Lett. (2002) 84:223–229.
   PubMed Web of Science ®Google Scholar
• ITO H, HIROTANI T, YAMAMOTO M, OGAWA H, KISHIMOTO T: Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. J. Gastroenterol (2002) 37\(Suppl. 14):56–61.
   Google Scholar
• NAKAHARA H, SONG J, SUGIMOTO M et al.: Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. (2003) 48:1521–1529.
   PubMed Web of Science ®Google Scholar
• ••Involvement of IL-6 on VEGF production.
   Google Scholar
• KEFFER J, PROBERT L, CAZLARIS H et al.: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. (1991) 10:4025–4031.
   PubMed Web of Science ®Google Scholar
• GROSSMAN RM, KRUEGER J, YOURISH D et al.: Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl Acad. Sci. USA (1989) 86:6367–6371.
   PubMed Web of Science ®Google Scholar
• FREI K, FREDRIKSON S, FONTANA A, LINK H: Interleukin-6 is elevated in plasma in multiple sclerosis. J. Neuroimmunol (1991) 31:147–153.
   PubMed Web of Science ®Google Scholar